Epithalon and Thymosin Alpha-1: What Clinics Should Understand About Sourcing
A rep will tell you Thymosin Alpha-1 is approved in thirty-five countries, and the striking part is that something close to it is true. The number I can actually source is thirty, from SciClone’s own SEC filings. What the pitch leaves out is that the United States is not among them, and that the peptide sitting next to it on the same order form has never been studied in a single registered clinical trial anywhere.
Those two products land on the same shelf, in the same category, often on the same invoice. Their FDA standing is similarly unsettled. Their evidence bases are not remotely comparable. So this Epithalon and Thymosin Alpha-1 sourcing guide walks through what each one actually is, how far apart their records sit, and what that means when you are vetting a supplier. It is background for purchasing decisions, not medical advice, and it recommends neither product for any patient or purpose.
One thing to settle before the rest of it makes sense. Neither peptide can currently be compounded from bulk drug substance in the United States, not at a 503A pharmacy and not at a 503B outsourcing facility. Everything below stands on that, and I will come back to why.
What Thymosin Alpha-1 actually is
Thymosin Alpha-1 is a naturally occurring, N-terminally acetylated peptide of 28 amino acids, originally isolated from thymosin fraction 5 of calf thymus. Its activity relates to immune modulation rather than structural repair, which alone separates it from most of the tissue repair category.
It also carries by far the deepest clinical record of anything in this cluster. Under the generic name thymalfasin and the brand name ZADAXIN, it has been studied for decades, largely in chronic hepatitis B and C, in cancer immunotherapy contexts, and in various immune-compromised settings. As of August 2026, ClinicalTrials.gov lists sixty-five registered studies involving it, ten of them Phase 4. The largest are a 606-patient study in hepatitis B related cirrhosis, a 508-patient study in acute necrotizing pancreatitis, and a 360-patient adjuvant study in hepatitis B related hepatocellular carcinoma.
In its final annual report to the SEC, SciClone stated that ZADAXIN “is approved in over 30 countries and may be used for the treatment of HBV, HCV, and certain cancers, and as an immune system enhancer according to the local regulatory approvals we have in these countries.” Those approvals sit primarily in Asia, the Middle East, and Latin America.
The United States is a different story. Thymosin Alpha-1 products, including ZADAXIN, have never received FDA marketing approval. The company reported holding orphan drug designations for thymalfasin in malignant melanoma and chronic hepatitis B in the US, and in hepatocellular carcinoma in the US and Europe, the hepatitis B designation dating to May 1991. Orphan designation is a development incentive, not an approval, and none of the three has ever converted into one.
What Epithalon actually is
Epithalon, also written Epitalon, which is the spelling the FDA and the chemical registries use, is a much smaller molecule, a tetrapeptide of just four amino acids. It emerged from Russian research into the pineal gland and aging, developed as a synthetic counterpart to an earlier pineal extract called epithalamin.
The Epithalon peptide is where the record thins dramatically. Published literature exists, roughly two hundred records, much of it originating from a single research tradition and focused on aging and telomere-related questions. What does not exist is registered clinical trial activity. A search of ClinicalTrials.gov for Epithalon, Epitalon, and epithalamin returns nothing at all. Not a completed trial, not a recruiting one, not a withdrawn one.
That is a meaningful finding rather than a technicality. It means no sponsor has registered a controlled human study of this peptide in the registry that serves as the international standard. When your team fields a patient question about what the research shows, that context matters.
The gap, side by side
This table is a regulatory awareness reference, not clinical guidance and not a purchasing recommendation. Candidacy and use belong with a licensed prescriber under the rules of your state.
| Consideration | Thymosin Alpha-1 | Epithalon |
|---|---|---|
| Size | 28 amino acids | 4 amino acids |
| Origin | Thymic peptide, immune modulation | Russian pineal and aging research |
| Registered trials | 65 on ClinicalTrials.gov, August 2026 | None found, August 2026 |
| Largest studies | Phase 4 trials of 606, 508 and 360 patients | No registered trials |
| Approval abroad | Over thirty countries per SciClone’s SEC filings | No comparable approvals |
| US status | Not FDA approved, orphan designation only | Not FDA approved |
| FDA compounding file | Nomination withdrawn, safety information called inadequate | Nomination withdrawn, no safety information identified for the proposed route |
| Advisory committee | Reviewed December 2024, committee voted against inclusion | Reviewed July 2026, committee voted in favor of inclusion |
| Compoundable from bulk today | No | No |
Read that table twice, because the lesson sits in the contrast, and in the last three rows especially. Two products with similar United States standing can have wildly different research histories behind them, and the regulatory outcomes can run in the opposite direction from what those histories would predict. Treating them as equivalent, in either direction, misleads your team and your patients.
Why approval abroad does not help you here
This is the point I most want clinic owners to internalize, because it is where good-faith mistakes happen.
Approval in another country reflects that country’s regulator reviewing a dossier under its own standards. It is genuinely meaningful information about a product’s research history, and the FDA itself weighs international marketing experience when it evaluates a substance for the bulks lists. What it does not do is confer any United States marketing authorization. It does not satisfy any criterion under section 503A, it does not change what a pharmacy here may compound, and it does not change what your clinic may claim. A peptide approved in thirty other countries and a peptide approved in none stand in the same place under United States compounding law if neither holds FDA approval.
So when a supplier leans on international approval as a selling point, the honest response is to treat it as background rather than as authorization. The follow-up question is simple and revealing: what is this substance’s status here, and what documentation can you show me for this specific lot? A serious supplier answers without flinching.
What the FDA has actually said about both
Both peptides sit in the FDA’s Category 2 file, the agency’s list for bulk substances that may present significant safety risks in compounding. Specifically, both appear in that page’s table of nominations that were later withdrawn by the nominators rather than in the active Category 2 list. That distinction matters, because substances in the withdrawn table are not under active agency evaluation. Neither appears in Category 1 either, which is where the FDA’s interim policies place nominated substances the agency may consider for enforcement discretion while it works through them.
One point worth keeping straight, because it gets stated backwards often. Category placement is an enforcement-policy signal, not the legal test. A substance is not barred from compounding because it landed in Category 2, and it would not become compoundable by moving out of it. The bar is statutory and sits in section 503A itself, which the section below covers.
The published concerns differ in a way worth knowing. For Thymosin Alpha-1, the FDA described possible immunogenicity risk for certain routes of administration along with complexities in peptide-related impurities and API characterization, and said the safety-related information is inadequate for the agency to sufficiently understand the extent of any safety issues. For Epitalon, the agency noted immunogenicity risk from potential aggregation and peptide-related impurities, and stated it lacks sufficient information to know whether the drug would cause harm if administered to humans.
You can follow the record on the FDA’s page for bulk drug substances used in compounding.
What the advisory committee did, and what it did not do
Most of the secondhand summaries get this wrong, so it is worth walking through slowly.
Thymosin Alpha-1 went before the FDA’s Pharmacy Compounding Advisory Committee on December 4, 2024. The FDA recommended against adding it to the 503A Bulks List, citing gaps in physicochemical characterization, limited evidence of effectiveness, and the safety concerns above. The committee agreed and voted against inclusion.
Epitalon went before the same committee on July 24, 2026, as part of a two-day session covering seven peptides. Two things about that session are easy to miss. The nominated use under review was insomnia, not aging and not telomere biology, which means the published literature does not speak to the indication that was actually on the table, and the FDA said as much. And the FDA again recommended against inclusion, but this time the committee overrode its own staff and voted in favor. Six of the seven peptides reviewed that week received positive votes. Only Emideltide, also called DSIP, was rejected.
A note on the tally, because you will see it quoted several ways and some of those quotations are stated with more confidence than the record supports. Contemporaneous reporting from the meeting and two subsequent law-firm summaries put the Epitalon vote at seven in favour and four against, with one abstention. One trade outlet has reported seven to five. Accounts of the same day’s other votes agree with each other, Semax at eight to five and Emideltide rejected six to seven, which makes the Epitalon discrepancy look like a counting difference on the day rather than a dispute about what happened. As of 20 August 2026 the FDA has not published minutes for this meeting; the only voting document posted to the meeting page is the draft list of questions put to the committee. So if an exact count matters to your own documentation, wait for the minutes and cite those. Every account agrees on the direction: it was close, and it went against the FDA staff recommendation.
So the peptide with sixty-five registered trials was turned down, and the peptide with none was recommended. Not a typo, and it is the clearest illustration I can give you that evidence quality and regulatory outcome are separate questions.
Now the part that gets misread. A committee recommendation is advice to the FDA, not authorization. The agency must still complete notice-and-comment rulemaking before anything is added to the 503A Bulks List, and it is free to decline. Nothing about the July vote changed what a pharmacy may lawfully compound today.
Why neither is compoundable from bulk right now
I said I would come back to this, because it is the single most important operational fact in the article and the one most likely to be papered over in a sales conversation.
Under section 503A, a compounding pharmacy may use a bulk drug substance only if that substance complies with the standards of an applicable USP or NF monograph, is a component of an FDA-approved drug, or appears on the 503A Bulks List. The statute adds two further requirements that get overlooked: the bulk substance must be manufactured by an establishment registered with the FDA under section 510, and it must be accompanied by a valid certificate of analysis. Neither Thymosin Alpha-1 nor Epithalon satisfies the first test at all.
The 503B route does not solve it either. The final 503B bulks list contains five substances, none of them peptides, and neither of these appears on the FDA’s drug shortage list.
So that is the legal position as of August 2026. It is a separate question from what is actually circulating, and separate again from how the FDA has chosen to prioritize enforcement. Enforcement posture is not permission, and a supplier who conflates the two is telling you something about how they will handle your account. If the answer to a direct status question is a shrug and a reference to what everyone else is doing, you have learned what you needed to learn.
Documentation standards, and where these two fall short
The standards below are what good sourcing looks like across this category generally. They are worth knowing precisely because they are how you will evaluate any peptide your clinic may lawfully obtain. Applied to these two specific substances today, they do not produce a lawful route, because the threshold question of substance eligibility fails before documentation is even reached.
Strong peptide documentation starts with a certificate of analysis tied to the exact lot, from an accredited third-party lab rather than the seller’s own bench. It should confirm identity, report purity, and include sterility and endotoxin testing for anything injectable. Check that the lot number on the certificate matches the number on the vial, since a mismatch turns the paperwork into decoration.
Confirm licensing as well, whether a product comes from a 503A pharmacy filling patient-specific prescriptions or an FDA-registered 503B outsourcing facility operating under stricter manufacturing standards. Then bear in mind what the section above establishes, because this is the trap. Licensure tells you the facility is legitimate. It does not tell you that a given substance is permitted at that facility. Both questions need answering, and for Thymosin Alpha-1 and Epithalon the second one currently answers itself.
Questions worth asking about these two specifically
If a supplier raises either substance with you, a few questions surface the relevant information quickly.
For Thymosin Alpha-1, ask about the source and the characterization. Its longer international history means a supplier may reference research or approvals tied to a specific manufactured product sold abroad, which is not the same thing as a compounded vial arriving at your clinic. Those are different things, and any documentation should describe what is actually being offered.
For Epithalon, ask how identity gets confirmed. A four amino acid peptide is a small molecule to characterize, and with no registered trial record and no established United States reference product, analytical paperwork would carry the entire weight of anyone’s confidence.
For both, the first question comes before either of those, and it is the eligibility question. Ask the supplier to identify which of the three section 503A criteria the substance satisfies. There is no correct answer available today, and how a supplier handles that is the most useful information you will get from the conversation.
What to do with this in practice
Keep the two mentally separate even though the category groups them. Train your team to describe each honestly, which means acknowledging that one has a long international research record and the other does not, that FDA reviewers recommended against both, and that neither holds FDA approval or a place on either bulks list.
Keep any discussion conservative and prescriber-directed, keep documentation matched to inventory, and re-check regulatory status before each reorder cycle rather than assuming last quarter’s answer still holds. That last point is not boilerplate this year. The FDA has not initiated rulemaking on the six peptides the committee recommended in July, has no statutory deadline for doing so, and is not obliged to follow the recommendation at all. Separately, the agency has said it will hold another advisory committee meeting before the end of February 2027, covering a different set of five substances including LL-37, GHK-Cu, Dihexa acetate, Melanotan II and PEG-MGF. That session will not revisit Epitalon or Thymosin Alpha-1.
The same analysis applies to the other substances the committee took up in July. BPC-157, TB-500 and KPV all received positive votes on the same non-binding basis, and none of them may be compounded from bulk today either. Treat every one of them as a separate status question to be re-checked against the FDA’s own lists, not as a category that moved.
Frequently asked questions
What should clinics know first from an Epithalon and Thymosin Alpha-1 sourcing guide?
That the two are far apart in research history despite similar United States standing, and that neither may currently be compounded from bulk. Thymosin Alpha-1 has sixty-five registered clinical trials and approval in over thirty countries. Epithalon has no registered trials at all. Neither holds FDA approval in the United States, and neither appears on the 503A or 503B bulks lists.
Is Thymosin Alpha-1 FDA approved?
No. It has not received FDA marketing approval in the United States, although thymalfasin holds orphan drug designations for chronic hepatitis B, malignant melanoma, and hepatocellular carcinoma. Orphan designation is a development incentive rather than an approval, and none of the three has led to a US approval. It is approved as a prescription medicine in a number of other countries.
Did the FDA advisory committee approve Epithalon in July 2026?
No. The committee voted to recommend adding Epitalon to the 503A Bulks List, against the FDA staff’s own recommendation, in a close vote. That is advice to the agency, not approval and not authorization. The FDA must still complete notice-and-comment rulemaking, has not initiated it, and is not obliged to follow the committee. Nothing has changed about what may lawfully be compounded today.
Was Thymosin Alpha-1 reviewed by the same committee?
Yes, on December 4, 2024, as a separate matter. The FDA recommended against adding it to the 503A Bulks List and the committee voted against inclusion. It was not part of the July 2026 session.
Does approval in other countries make a peptide legal to use here?
No. Foreign approval reflects another regulator’s review under its own standards. It confers no United States marketing authorization and satisfies no criterion under section 503A. It is useful background about a product’s research history, but it does not change what a pharmacy may compound here or what a clinic may claim.
Why does Epithalon have so little clinical evidence?
Its published research comes largely from one research tradition focused on aging and pineal biology, and no sponsor has registered a controlled human trial of it on ClinicalTrials.gov. The FDA has separately stated it identified no safety information for the proposed route of administration, and no published efficacy data for insomnia, the use that was under review.
What documentation standards apply to peptides in this category?
A lot-specific certificate of analysis from an accredited third-party lab covering identity, purity, sterility, and endotoxin testing, with the lot number matching the vial, plus proof of the pharmacy’s licensing as 503A or 503B and clear answers on storage and shipping. Confirm separately that the substance itself is permitted at that facility, since licensure and substance eligibility are two different questions. For Thymosin Alpha-1 and Epithalon, the eligibility question currently fails, so no documentation package makes bulk compounding of them lawful.
Disclaimer
This article is general educational and regulatory-tracking information for licensed clinics and healthcare professionals. It is not medical advice and it is not legal advice. It is not a treatment recommendation, and it does not claim that either peptide is safe, effective, or appropriate for any use. Phoenix Meds Inc. is a non-dispensing sourcing coordination company. We do not manufacture, compound, prescribe, or dispense pharmaceuticals. Nothing in this article is an offer to supply either substance. Neither Thymosin Alpha-1 nor Epithalon holds FDA approval in the United States, neither appears on the 503A or 503B bulks lists, and foreign approvals do not change United States requirements. Regulatory status changes over time, so verify current FDA and state rules before acting. Rely only on qualified prescribers for clinical decisions, and source only through properly licensed pharmacies and wholesalers.